Document is current
Any future updates will be listed below
-
Authors
Moccia, Marcello https://orcid.org/0000-0003-2613-3090
Loperto, Ilaria
Lanzillo, Roberta
Capacchione, Antonio
Carotenuto, Antonio
Triassi, Maria
Brescia Morra, Vincenzo
Palladino, Raffaele
-
Funding
Funding for this research was provided by:
Merck KGaA (2019)
- License Information
-
More Information
Article History
Received: 18 May 2020
Accepted: 17 August 2020
First Online: 26 August 2020
Ethics approval and consent to participate
: The study was approved by the Federico II Ethics Committee (355/19). All patients signed informed consent authorising the use of anonymised data collected routinely as part of the clinical practice, in line with data protection regulation (GDPR EU2016/679). The study was performed in accordance with good clinical practice and Declaration of Helsinki.
: Not applicable.
: Marcello Moccia has received research grants from ECTRIMS-MAGNIMS, UK MS Society, and Merck; honoraria from Biogen, Merck, Novartis, and Roche; and consulting fees from Veterans Evaluation Services. Roberta Lanzillo has received honoraria from Almirall, Biogen, Merck, Teva, Roche, Novartis, Sanofi-Genzyme, and Teva. Antonio Capacchione is an employee of Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany. Vincenzo Brescia Morra has received research grants from Italian MS Federation; and honoraria from Almirall, Bayer, Biogen, Merck, Roche, Novartis, Sanofi-Genzyme, and Teva. Other authors have nothing to disclose.
